165 related articles for article (PubMed ID: 19388179)
1. CROI 2009: a few key presentations on antiretroviral therapy.
Gallant JE
AIDS Read; 2009 Apr; 19(4):129-30, C3. PubMed ID: 19388179
[No Abstract] [Full Text] [Related]
2. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
[No Abstract] [Full Text] [Related]
3. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
4. Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
[No Abstract] [Full Text] [Related]
5. Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.
Wilkin TJ; Taylor B; Olender S; Hammer SM
Top HIV Med; 2008; 16(1):31-60. PubMed ID: 18441381
[TBL] [Abstract][Full Text] [Related]
6. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Raffi F; Rachlis A; Brinson C; Arasteh K; Górgolas M; Brennan C; Pappa K; Almond S; Granier C; Nichols WG; Cuffe RL; Eron J; Walmsley S
AIDS; 2015 Jan; 29(2):167-74. PubMed ID: 25387312
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Depatureaux A; Leoz M; Le Moal G; Pathé JP; Pavie J; Batisse D; Daneluzzi V; Genet P; Gerard L; Lascaux-Cametz AS; Lambolez T; Chennebault JM; Plantier JC
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):e1-3. PubMed ID: 22918125
[No Abstract] [Full Text] [Related]
9. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
10. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
[TBL] [Abstract][Full Text] [Related]
11. Advances in HIV therapeutics: the 14th CROI.
Boyle BA; Elion R; Cohen CJ; Moyle GJ; Sax P; Frank I
AIDS Read; 2007 May; 17(5):268-70, 272-4, 283-6. PubMed ID: 17532664
[No Abstract] [Full Text] [Related]
12. Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
Casado JL; Bañón S
Expert Rev Clin Pharmacol; 2015; 8(6):709-18. PubMed ID: 26517111
[TBL] [Abstract][Full Text] [Related]
13. Anti-HIV agents. Merck integrase inhibitor.
TreatmentUpdate; 2006; 18(4):3-4. PubMed ID: 17205652
[No Abstract] [Full Text] [Related]
14. Antiretroviral therapy-associated diseases are common in the long-term.
Lanzafame M; Lattuada E; Zoppini G; Vento S
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):931-2. PubMed ID: 21182461
[No Abstract] [Full Text] [Related]
15. Raltegravir: is a 400 mg once-daily dose enough?
Lanzafame M; Hill A; Lattuada E; Calcagno A; Bonora S
J Antimicrob Chemother; 2010 Mar; 65(3):595-7. PubMed ID: 20071368
[No Abstract] [Full Text] [Related]
16. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review.
Gray J; Young B
AIDS Patient Care STDS; 2009 Sep; 23(9):689-90. PubMed ID: 19663717
[No Abstract] [Full Text] [Related]
17. 'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.
Linde M
Posit Living; 2002; 11(3):8-9, 16, 44. PubMed ID: 12035759
[No Abstract] [Full Text] [Related]
18. 13th annual HIV drug guide.
Djuricich P; Vázquez E
Posit Aware; 2009; 20(2):28-55. PubMed ID: 19280745
[No Abstract] [Full Text] [Related]
19. 12th annual HIV drug guide.
Diaz-Linares M; Vázquez E; Gallant J; Delaney M
Posit Aware; 2008; 19(1):19-48. PubMed ID: 18546577
[No Abstract] [Full Text] [Related]
20. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
